[1. The prevention or delay of type 2 diabetes. Diabetes Care. 2002; 25:742-9.10.2337/diacare.25.4.74211919135]Open DOISearch in Google Scholar
[2. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30:753-9.10.2337/dc07-992017327355]Open DOISearch in Google Scholar
[3. Richard EP, Matfin G. Pre-diabetes: Clinical Relevence and Therapeutic Approach. Br J Diabetes Vasc Dis. 2007; 7:120-9.10.1177/14746514070070030401]Open DOISearch in Google Scholar
[4. Group TDS. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003; 26:61-9.10.2337/diacare.26.1.6112502659]Search in Google Scholar
[5. Qiao Q, Hu G, Tuomilehto J, Nakagami T, Balkau B, Borch-Johnsen K, et al. Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care. 2003; 26:1770-80.10.2337/diacare.26.6.177012766108]Search in Google Scholar
[6. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005; 128:1-11.]Search in Google Scholar
[7. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005; 5:129-34.10.1016/j.coph.2005.01.00115780820]Open DOISearch in Google Scholar
[8. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005; 6:13-21.10.1111/j.1467-789X.2005.00159.x15655035]Open DOISearch in Google Scholar
[9. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52:1779-85.10.2337/diabetes.52.7.177912829646]Open DOISearch in Google Scholar
[10. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004; 27:2450-7.10.2337/diacare.27.10.245015451915]Open DOISearch in Google Scholar
[11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22:233-40.10.2337/diacare.22.2.23310333939]Search in Google Scholar
[12. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002; 25:829-34.10.2337/diacare.25.5.829]Open DOISearch in Google Scholar
[13. Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-thanoptimum blood glucose concentration: comparative risk assessment. Lancet. 2006; 368:1651-9.10.1016/S0140-6736(06)69700-6]Open DOISearch in Google Scholar
[14. Williams DR, Wareham NJ, Brown DC, Byrne CD, Clark PM, Cox BD, et al. Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. Diabet Med. 1995; 12:30-5.10.1111/j.1464-5491.1995.tb02058.x]Open DOISearch in Google Scholar
[15. Claudi T, Midthjell K, Holmen J, Fougner K, Kruger O, Wiseth R. Cardiovascular disease and risk factors in persons with type 2 diabetes diagnosed in a large population screening: the Nord-Trondelag Diabetes Study, Norway. J Intern Med. 2000; 248:492-500.10.1046/j.1365-2796.2000.00759.x]Open DOISearch in Google Scholar
[16. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980; 1:1373-6.10.1016/S0140-6736(80)92651-3]Open DOISearch in Google Scholar
[17. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999; 340:14-22.10.1056/NEJM1999010734001039878640]Open DOISearch in Google Scholar
[18. Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care. 1994; 17:1330-6.10.2337/diacare.17.11.13307821175]Open DOISearch in Google Scholar
[19. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R,et al. Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance. Diabetes Care. 1997; 20:627-31.10.2337/diacare.20.4.6279096992]Open DOISearch in Google Scholar
[20. Goff DC Jr, D’Agostino RB, Haffner SM, Saad MF, Wagenknecht LE. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2000; 23:1006-11.10.2337/diacare.23.7.100610895855]Open DOISearch in Google Scholar
[21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-9.10.1007/BF002808833899825]Open DOISearch in Google Scholar
[22. Aydin Y, Berker D, Ustun I, Gul K, Erden G, Kutlucan A, et al. Evaluation of carotid intima media thickness in impaired fasting glucose and impaired glucose tolerance. Minerva Endocrinol. 2011; 36:171-9.]Search in Google Scholar
[23. Brohall G, Oden A, Fagerberg B. Carotid artery intimamedia thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med. 2006; 23:609-16.10.1111/j.1464-5491.2005.01725.x16759301]Open DOISearch in Google Scholar
[24. Karasik A: Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum. Ann Med. 2005; 37:250-8.10.1080/0785389051003736516019723]Open DOISearch in Google Scholar
[25. Guo LL, Pan Y, Jin HM. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Nephrol Dial Transplant. 2009; 24:1876-83.10.1093/ndt/gfn77019164322]Search in Google Scholar
[26. Gokulakrishnan K, Indulekha K, Ganesan S, Anuradha S, Mohan V. Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). Diabetes Technol Ther. 2010; 12:109-15.10.1089/dia.2009.010020105040]Open DOISearch in Google Scholar
[27. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51:2796-803.10.2337/diabetes.51.9.279612196473]Open DOISearch in Google Scholar
[28. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003; 46:1211-9.10.1007/s00125-003-1169-612879253]Open DOISearch in Google Scholar
[29. Nilsson PM, Engström G, Hedblad B, Frystyk J, Persson MM, Berglund G, et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol. 2006; 26:2758-62.10.1161/01.ATV.0000249638.01416.4b17038635]Open DOISearch in Google Scholar
[30. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-34.10.1001/jama.286.3.32711466099]Search in Google Scholar
[31. Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, et al. Genetic variation, Creactive protein levels, and incidence of diabetes. Diabetes. 2007; 56:872-8.10.2337/db06-092217327459]Open DOISearch in Google Scholar
[32. Shahid HS, Kurdi MI, Zohair AA. Serum highsensitivity C-reactive protein and lipoprotein(a) levels: a comparison between diabetic and non-diabetic patients with coronary artery disease. Med J Malaysia. 2011; 66:113-6.]Search in Google Scholar